Vimarsana
Biggest News Aggregation in the World

Page 25 - Clinical Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Program Today - Breaking & Trending Today

Takeda Presents Full Data Set from Phase 3 ADVANCECIDP 1 Clinical Trial Investigating HYQVIA as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy CIDP at PNS Annual Meeting - Vimarsana News

Takeda Presents Full Data Set from Phase 3 ADVANCECIDP 1 Clinical Trial Investigating HYQVIA as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy CIDP at PNS Annual Meeting

Published: June 21, 2023

TakedaTSE4502NYSETAK today announced full results from the pivotal Phase 3 ADVANCECIDP 1 clinical trial investigating HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase as maintenance therapy in adult patients with chronic inflammatory demyelinating polyneuropathy CIDP.

Source: businesswireindia.com
Related Topics:
City OfUnited KingdomUnited StatesKristina AllikmetsLauren PadovanRobert HaddenPeripheral Nerve SocietyEuropean UnionClinical ProgramExchange CommissionKing College HospitalTakeda Pharmaceutical Company LimitedEuropean Medicines AgencyInternational MediaResearch Development For Takeda PlasmaClinically Significant ReductionRelapse RateDelayed TimeRelapse ComparedPlacebo When UsedMaintenance TherapyAdult PatientsProgram Reflects TakedaInvestigating ImmunoglobinNerve Society
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting - Vimarsana News

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Published: June 20, 2023

Pivotal Phase 3 Findings with HYQVIA [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase] Showed a Clinically Significant Reduction in Relapse Rate as well as a Delayed Time to... | June 20, 2023

Source: marketscreener.com
Related Topics:
City OfUnited KingdomUnited StatesKristina AllikmetsRobert HaddenClinical ProgramTakeda Pharmaceutical Company LimitedEuropean Medicines AgencyKing College HospitalPeripheral Nerve SocietyResearch Development For Takeda PlasmaExchange CommissionEuropean UnionNerve SocietyAnnual MeetingPeripheral Nervous SystemPlasma Derived Therapies BusinessInflammatory Neuropathy CauseRasch Built Overall Disability ScaleConsultant NeurologistCollege HospitalRecombinant Human HyaluronidaseProduct CharacteristicsBaxalta Innovations GmbhAnnual Report
Intellia Therapeutics Announces New Positive Clinical Data - Vimarsana News

Intellia Therapeutics Announces New Positive Clinical Data

Published: June 11, 2023

Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients...

Source: globenewswire.com
Related Topics:
United KingdomIan KarpJohn LeonardAlina LiTimothyj CraigMatt CrensonExchange CommissionCorporate CommunicationsIntellia Therapeutics IncBiomedical Sciences At Penn State UniversityEuropean Academy Of AllergyClinical ProgramExtended PhaseEuropean AcademyClinical ImmunologyHybrid CongressIntellia PresidentChief Executive OfficerRate ReductionBiomedical SciencesPenn State UniversityIntellia TherapeuticsPrivate Securities Litigation Reform ActVice PresidentInvestor Relations
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients - Vimarsana News

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Published: June 5, 2023

– PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity – – PRGN-3005 cells demonstrated expansion...

Source: prnewswire.com
Related Topics:
United StatesMaryl Nora DisisStevenm HarasymHelen SabzevariPrecigen UltraClinical ProgramYiv AdministrationWorld Health OrganizationPrecigen IncExchange CommissionAmerican Cancer Society Ovarian Special SectionFred Hutchinson Cancer Research CenterInternational Agency For Research On CancerUniversity Of WashingtonDrug AdministrationAmerican Cancer SocietyDose LevelEscalation PatientTumor BurdenSerious Adverse EventsCytokine Release SyndromeRelated AdverseRelease SyndromeTarget TumorTarget Lesion Response
Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023 - Vimarsana News

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

Published: May 31, 2023

Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the studyIntellia to host investor webcast on Monday,... | May 31, 2023

Source: marketscreener.com
Related Topics:
Noord HollandUnited KingdomJeremy PetersenAlina LiTimothyj CraigIan KarpMatt CrensonBridge CommunicationsCorporate CommunicationsPenn State UniversityEuropean Academy Of AllergyClinical ProgramAmsterdam University Medical CenterBiomedical SciencesGlobenewswire IncIntellia Therapeutics IncExchange CommissionHybrid CongressState UniversityIntellia TherapeuticsPrivate Securities Litigation Reform ActVice PresidentInvestor RelationsNc Stock ExchangePress Release